Advertisement

Neuroscience and Behavioral Physiology

, Volume 38, Issue 5, pp 443–448 | Cite as

Changes in anxiety in abstinence correlate with the state of the nigrostriatal system in the rat hippocampus

  • D. I. Peregud
  • O. N. Vorontsova
  • A. A. Yakovlev
  • L. F. Panchenko
  • N. V. Gulyaeva
Article

Abstract

Opiate dependence results from impairments of neuronal plasticity, i.e., so-called aberrant neuroplasticity, formation of which involves long-term structural-functional rearrangements persisting even during drug abstinence. Nitric oxide (NO) is involved both in mediating the effects of opiates and in the mechanisms of some types of neuroplasticity, so NO may potentially take part in the development of psychopathological processes on opiate withdrawal. The present study addressed measures of the nitrergic system (nitric oxide synthase (NOS) activity and nitrite and nitrate (NO x ) concentrations) in areas of the rat brain; anxiety was also assessed, in terms of behavioral measures in the elevated plus maze, during morphine withdrawal. NOS activity was found to increase by day 3, while the NO x concentration was increased by day 6 of withdrawal, these changes being seen only in the hippocampus. At six days after morphine withdrawal, rats showed more entries into the open arms of the elevated plus maze and remained in these arms longer. Correlations were found between measures of the NO system in the hippocampus and the behavior of the animals in the maze. These results suggest that changes in the activity of the nitrergic system in the hippocampus represent one of the molecular mechanisms impairing the behavior of animals in abstinence.

Key words

hippocampus behavior elevated plus maze nitric oxide morphine abstinence 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    D. I. Peregud, A. A. Yakovlev, L. K. Egorova, M. V. Onufriev, L. F. Panchenko, and N. V. Gulyaeva, “Effects of acute administration of morphine on the rat brain nitrergic system,” Neirokhimiya, 21, No. 3, 208–213 (2004).Google Scholar
  2. 2.
    Yu. P. Sivolap, “The question of the particular psychopathology of opioid addition,” Narkologiya, No. 5, 51–53 (2006).Google Scholar
  3. 3.
    M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein binding,” Anal. Biochem., 72, No. 1–2, 248–254 (1976).PubMedCrossRefGoogle Scholar
  4. 4.
    D. S. Bredt and S. H. Snyder, “Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum,” Proc. Natl. Acad. Sci. USA, 86, No. 22, 9030–9033 (1989).PubMedCrossRefGoogle Scholar
  5. 5.
    J. D. Bremner, “Brain imaging in anxiety-disorders,” Exptl. Rev. Neurother., 4, No. 2, 275–284 (2004).CrossRefGoogle Scholar
  6. 6.
    Contemporary Clinical Neuroscience: Glutamate and addiction, B. H. Herman et al., (eds.), Human Press Inc., Totowa, NJ (2003).Google Scholar
  7. 7.
    B. Cuéllar, A. P. Fernández, I. Lizasoain, M. A. Moro, P. Lorenzo, M. I. Bentura, J. Rodrigo, and J. C. Leza, “Up-regulation of neuronal NO synthase immunoreactivity in opiate dependence and withdrawal,” Psychopharmacology, 148, No. 1, 66–73 (2000).PubMedCrossRefGoogle Scholar
  8. 8.
    J. Garcia-Estrada, G. Tapia-Arizmendi, A. Feria-Velasco, and V. Aleman, “Ultrastructural alterations in caudate nucleus, cerebral cortex and hippocampus produced by morphine,” Gen. Pharmacol., 19, No. 6, 841–848 (1988).PubMedGoogle Scholar
  9. 9.
    J. Garthwaite, “Glutamate, nitric oxide and cell-cell signaling in the nervous system,” TiNS, 14, No. 2, 60–67 (1991).PubMedGoogle Scholar
  10. 10.
    K. Grasing, A. Wang, and S. Schlussman, “Behavioral measures of anxiety during opiate withdrawal,” Behav. Brain Res., 80, No. 1–2, 195–201 (1996).PubMedCrossRefGoogle Scholar
  11. 11.
    K. P. Gudehithlu and H. N. Bhargava, “Differential binding of [3H]MK-801 to brain regions and spinal cord of mice treated chronically with morphine,” Gen. Pharmacol., 27, No. 1, 91–94 (1996).PubMedCrossRefGoogle Scholar
  12. 12.
    M. Guo, N.-J. Xu, Y.-T. Li, J.-Y. Yang, C.-F. Wu, and G. Pei, “Morphine modulates glutamate release in the hippocampal CAl area in mice,” Neurosci. Lett., 381, No. 102, 12–15 (2005).PubMedCrossRefGoogle Scholar
  13. 13.
    G. A. Higgins and E. M. Sellers, “Antagonist-precipitated opioid withdrawal in rats: evidence for dissociations between physical and motivational signs,” Pharmacol. Biochem. Behav., 48, No. 1, 1–8 (1994).PubMedCrossRefGoogle Scholar
  14. 14.
    C. G. Jang, R. W. Rockhold, and I. K. Ho, “An autoradiographic study of [3H]AMPA receptor binding and in situ hybridization of AMPA sensitive glutamate receptor A (GluR-A) subunits following morphine withdrawal in the rat brain,” Brain Res. Bull., 52, No. 3, 217–221 (2000).PubMedCrossRefGoogle Scholar
  15. 15.
    K. Kumar and H. Bhargava, “Time course of the changes in central nitric oxide synthase activity following chronic treatment with morphine in the mouse: reversal by naltrexone,” Gen. Pharmacol., 29, No. 2, 223–227 (1997).PubMedGoogle Scholar
  16. 16.
    J. C. Leza, I. Lizasoain, O. San-Martin-Clark, and P. Lorenzo, “Morphine-induced changes in cerebral and cerebellar nitric oxide synthase activity,” Eur. J. Pharmacol., 285, No. 1, 95–98 (1995).PubMedCrossRefGoogle Scholar
  17. 17.
    C. Lino De Oliveira, E. A. Del Bel, and F. S. Guimaraes, “Effects of L-NOARG on plus-maze performance in rats,” Pharmacol. Biochem. Behav., 56, No. 1, 55–59 (1997).CrossRefGoogle Scholar
  18. 18.
    I. Lizasoain, J. C. Leza, B. Cuellar, M. A. Moro, and P. Lorenzo, “Inhibition of morphine withdrawal by lamotrigine: involvement of nitric oxide,” Eur. J. Pharmacol., 299, No. 1–3, 41–45 (1996).PubMedCrossRefGoogle Scholar
  19. 19.
    T. P. Misko, R. J. Schilling, D. Salvemini, W. M. Moore, and M. G. Currie, “A fluorometric assay for the measurement of nitrite in biological samples,” Anal. Biochem., 214, No. 1, 11–16 (1993).PubMedCrossRefGoogle Scholar
  20. 20.
    S. Moncada, R. M. J. Palmer, and E. A. Higgs, “Nitric oxide: physiology, pathophysiology, and pharmacology,” Pharmacol. Rev., 43, No. 2, 109–142 (1991).PubMedGoogle Scholar
  21. 21.
    M. E. Monzon, M. M. Varas, and S. R. De Barioglio, “Anxiogenesis induced by nitric oxide synthase inhibition and anxiolytic effect of melanin-concentrating hormone (MCH) in rat brain,” Peptides, 22, No. 7, 1043–1047 (2001).PubMedCrossRefGoogle Scholar
  22. 22.
    E. J. Nestler, “Molecular basis of long-term plasticity underlying addiction,” Nat. Rev. Neurosci., 2, No. 2, 119–128 (2001).PubMedCrossRefGoogle Scholar
  23. 23.
    E. J. Nestler, B. T. Hope, and K. L. Widnell, “A model for the molecular basis of neuronal plasticity,” Neuron, 11, No. 6, 995–1006 (1993).PubMedCrossRefGoogle Scholar
  24. 24.
    S. Ohkuma and M. Katsura, “Nitric oxide and peroxynitrite as factors to stimulate neurotransmitter release in the CNS,” Progr. Neurobiol., 64, No. 1, 97–108 (2001).CrossRefGoogle Scholar
  25. 25.
    S. Rahman, R. Ali Khan, and A. Kumar, “Experimental study of the morphine de-addiction properties of Delphinium denudatum Wall,” BMC Compl. Alt. Med., 2, 6 (2002).CrossRefGoogle Scholar
  26. 26.
    T. Robinson, G. Gorny, V. R. Savage, and B. Kolb, “Widespread but regionally specific effects of experimenter-versus self-administered morphine on dendritic spines in the nucleus accumbens, hippocampus, and neocortex of adult rats,” Synapse, 46, No. 4, 271–279 (2002).PubMedCrossRefGoogle Scholar
  27. 27.
    T. E. Robinson and B. Kolb, “Structural plasticity associated with exposure to drugs of abuse,” Neuropharmacology, 47, Supplement 1, 33–46 (2004).PubMedCrossRefGoogle Scholar
  28. 28.
    H. Sahrei, G. Poorheidari, M. Foadaddini, A. Khoshbaten, A. Asgari, A. Noroozzadeh, H. Ghoshooni, S. H. Firoozabadi, and M. R. Zarrindast, “Effects of nitric oxide on morphine self-administration in rat,” Pharmacol. Biochem. Behav., 77, No. 1, 111–116 (2004).CrossRefGoogle Scholar
  29. 29.
    M. Sala, M. P. Leone, P. Lampugnani, D. Bradia, D. Frattola, and E. Gori, “EEG power spectra and behavioural correlates in rats given chronic morphine. Lack of residual long-term EEG and neuronal changes,” Pharmacol. Res., 32, No. 1–2, 95–103 (1995).PubMedCrossRefGoogle Scholar
  30. 30.
    F. Salmanzadeh, Y. Fathollahi, S. Semnanian, and M. Shafizadeh, “Long-term potentiation as an electrophysiological assay for morphine dependence and withdrawal in rats: an in vitro study,” J. Neurosci. Meth., 124, No. 2, 189–196 (2003).CrossRefGoogle Scholar
  31. 31.
    G. Schulteis and G. F. Koob, “Reinforcement processes in opiate addiction: a homeostatic model,” Neurochem. Res., 21, No. 11, 1437–1454 (1996).PubMedCrossRefGoogle Scholar
  32. 32.
    G. Schulteis, M. Yackey, V. Risbrough, and G. F. Koob, “Anxiogenic-like effects of spontaneous and naloxone-precipitated opiate withdrawal in the elevated plus-maze,” Pharmacol. Biochem. Behav., 60, No. 3, 727–731 (1998).PubMedCrossRefGoogle Scholar
  33. 33.
    S. H. Snyder, “Nitric oxide and neurons,” Curr. Opin. Neurobiol., 2, No. 3, 323–327 (1992).PubMedCrossRefGoogle Scholar
  34. 34.
    I. T. Uzbaya and M. W. Oglesby, “Nitric oxide and substance dependence,” Neurosci. Biobehav. Rev., 25, No. 1, 43–52 (2001).CrossRefGoogle Scholar
  35. 35.
    A. F. Vanin, “Dinitrosyl iron complexes and S-nitrosothiols are two possible forms for stabilization and transport of nitric oxide in biological systems,” Biochemistry (Moscow), 63, No. 7, 782–793 (1998).Google Scholar
  36. 36.
    N. J. Xu, L. Bao, H. P. Fan, G. B. Bao, L. Pu, Y. J. Lu, C. F. Wu, X. Zhang, and G. J. Pei, “Morphine withdrawal increases glutamate uptake and surface expression of glutamate transporter GLT1 at hippocampal synapses,” J. Neurosci., 23, No. 11, 4775–4784 (2003).PubMedGoogle Scholar
  37. 37.
    G. H. Zhang, B. J. Wang, and X. Wu, “Study on the changes of ncNOS in chronic heroin dependence and spontaneous withdrawal in rats,” Fa. Yi. Xue. Za. Zhi., 19, No. 2, 68–71 (2003).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2008

Authors and Affiliations

  • D. I. Peregud
    • 1
  • O. N. Vorontsova
    • 2
  • A. A. Yakovlev
    • 2
  • L. F. Panchenko
    • 1
  • N. V. Gulyaeva
    • 2
  1. 1.Federal State National Scientific Center of Drug AddictionRussian Ministry of HealthMoscowRussia
  2. 2.Institute of Higher Nervous Activity and NeurophysiologyRussian Academy of SciencesMoscowRussia

Personalised recommendations